Copyright
©The Author(s) 2018.
World J Gastroenterol. Feb 28, 2018; 24(8): 917-928
Published online Feb 28, 2018. doi: 10.3748/wjg.v24.i8.917
Published online Feb 28, 2018. doi: 10.3748/wjg.v24.i8.917
Table 2 Baseline characteristics and renal outcome of the treated and untreated hepatitis B virus-infected chronic kidney disease patients (n = 3358), 1997-2012
| Variable | Overall HBV patients (n = 3358) | Propensity score-matched HBV patients (n = 1768) | ||||
| Treated (n = 442) | Untreated (n = 2916) | P value | Treated (n = 442) | Untreated (n = 1326) | P value | |
| Sex | < 0.0001 | 0.76 | ||||
| Men | 319 (72.2) | 1713 (58.7) | 319 (72.2) | 967 (72.9) | ||
| Women | 123 (27.8) | 1203 (41.3) | 123 (27.8) | 359 (27.1) | ||
| Age (yr, mean ± SD) | 51.0 ± 13.9 | 48.1 ± 14.4 | < 0.0001 | 51.0 ± 13.9 | 51.6 ± 14.7 | 0.49 |
| Interval to start nucleos(t)ide analogue therapy (yr, mean ± SD) | 1.2 ± 1.9 | - | 1.2 ± 1.9 | - | ||
| Nucleos(t)ide analogue therapy duration (yr, mean ± SD) | 0.8 ± 0.8 | - | 0.8 ± 0.8 | - | ||
| Comorbidity | ||||||
| Diabetes | 141 (31.9) | 749 (25.7) | 0.006 | 141 (31.9) | 424 (32.0) | 0.98 |
| Hypertension | 150 (33.9) | 884 (30.3) | 0.12 | 150 (33.9) | 457 (34.5) | 0.84 |
| Coronary heart disease | 59 (13.4) | 316 (10.8) | 0.12 | 59 (13.4) | 198 (14.9) | 0.41 |
| Hyperlipidemia | 108 (24.4) | 695 (23.8) | 0.78 | 108 (24.4) | 334 (25.2) | 0.75 |
| Cirrhosis | 59 (13.4) | 139 (4.8) | < 0.0001 | 59 (13.4) | 135 (10.2) | 0.07 |
| Urbanization level | 0.45 | 0.88 | ||||
| Urban | 129 (29.2) | 892 (30.6) | 129 (29.2) | 381 (28.7) | ||
| Suburban | 199 (45.0) | 1351 (46.3) | 199 (45.0) | 615 (46.4) | ||
| Rural | 114 (25.8) | 673 (23.1) | 114 (25.8) | 330 (24.9) | ||
| Enrolee category | 0.32 | 0.61 | ||||
| 1 + 2 | 161 (36.4) | 1122 (38.5) | 161 (36.4) | 460 (34.7) | ||
| 3 | 190 (43.0) | 1278 (43.8) | 190 (43.0) | 606 (45.7) | ||
| 4 | 91 (20.6) | 516 (17.7) | 91 (20.6) | 260 (19.6) | ||
| No. of medical visits (mean ± SD) | 26.5 ± 18.2 | 26.1 ± 20.8 | 0.75 | 26.5 ± 18.2 | 26.3 ± 19.3 | 0.90 |
| Charlson comorbidity index score (mean ± SD) | 1.9 ± 2.1 | 1.6 ± 1.9 | < 0.0001 | 1.9 ± 2.1 | 1.9 ± 2.2 | 0.79 |
| Propensity score (mean ± SD) | 1.6 ± 0.7 | 1.3 ± 0.6 | < 0.0001 | 1.6 ± 0.7 | 1.5 ± 0.7 | 0.51 |
| End-stage renal disease | ||||||
| Follow-up year (mean ± SD) | 7.6 ± 4.3 | 8.9 ± 3.9 | < 0.0001 | 7.6 ± 4.3 | 8.5 ± 4.0 | < 0.0001 |
| Total follow-up (person-year) | 3359 | 26101 | < 0.0001 | 3359 | 22478 | < 0.0001 |
| Event | 5 (1.1) | 197 (6.8) | < 0.0001 | 5 (1.1) | 108 (8.1) | < 0.0001 |
- Citation: Chen YC, Li CY, Tsai SJ, Chen YC. Nationwide cohort study suggests that nucleos(t)ide analogue therapy decreases dialysis risk in Taiwanese chronic kidney disease patients acquiring hepatitis B virus infection. World J Gastroenterol 2018; 24(8): 917-928
- URL: https://www.wjgnet.com/1007-9327/full/v24/i8/917.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i8.917